A project which aims to support early detection and prevent deterioration of chronic kidney disease has begun in Salford.
Supported by AstraZeneca, as part of a Joint Working Agreement, it is a collaborative project involving primary and secondary care organisations.
The aim of the project is to help clinicians identify how many people are developing, or living with, chronic kidney disease and associated conditions. It focuses on early detection to ensure people living with or at risk of chronic kidney disease can receive the right care, early. The ultimate goal is to help people with or at risk of chronic kidney disease to avoid complications and disease progression.
The project has the potential to reduce the number of people needing dialysis and transplants over time, as well as reducing the number of people dying from chronic kidney disease and its associated complications.
It aims to help deliver care to patients where and when they need it, by improving the understanding of population risk using prediction models.
Dr James Ritchie, Renal specialist, Chief Clinical Information Officer and Deputy Director of Research – Digital and Artificial Intelligence at Salford Royal, said: “This is a very exciting piece of work and we’re really pleased to be supported by AstraZeneca. The earlier your risk of chronic kidney disease is identified, the more we are able to reduce the risk of disease progression and offer the best care. We can therefore provide you with better self-management support within community healthcare settings. By acting early, we have the potential to help improve the lives of people living in the Greater Manchester area.”